前收市價 | 38.55 |
開市 | 29.42 |
買盤 | 28.70 |
賣出價 | 30.45 |
拍板 | 115.00 |
到期日 | 2024-07-19 |
今日波幅 | 29.42 - 29.42 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 2.54k |
美股在5月最後交易日個別發展,道瓊斯指數發力,升1.5%,以點數計大升逾570點,為今年以來最佳單日表現。納指周五平收,不過五月大升6.88%,跑贏另外兩指數。個人消費支出(PCE)4月份增長放緩,符合市場預期,美國國債息率稍為回落,市場維持九月份50%機會減息的預期。個別業績股大幅波動,電腦廠商Dell業績雖然好過預期,大跌18%,服裝零售商業績好過預期,大升28%。
On Friday, the FDA approved Moderna Inc’s (NASDAQ:MRNA) mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine to protect adults aged 60 and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA product from Moderna, the first being the famed COVID-19 vaccine. Earlier this month, the FDA, citing administrative constraints, delayed the review of the vaccine’s applicat
The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.